Topical non-steroidal antiinflammatory medicines in osteoarthritis treatment in patients with concomitant pathology


DOI: https://dx.doi.org/10.18565/therapy.2021.10.61-68

Gaydukova I.Z., Bashkinov A.R., Inamova O.V.

1) I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia, Saint Petersburg; 2) Clinical Rheumatology Hospital No. 25, Saint Petersburg
Abstract. Topical NSAIDs are an effective alternative to systemic forms of this class of medicines in patients with knee joints osteoarthritis (OA), concomitant pathology and high risk of developing unwanted reactions to the treatment.
The purpose of current work is to assess the frequency and efficacy of the use of topical NSAIDs in patients with knee joints OA and concomitant pathology.
Material and methods. The frequency and duration of the use of topical NSAIDs in patients with primary knee joints OA for the period 2000-2020 was estimated according to the register of rheumatic diseases of St. Petersburg. A collection of information about the severity of pain in the knee joints is carried out on a numerical rating scale for a month preceding the appeal to the doctor. The number and occurrence of comorbide conditions and the intensity of pain in patients receiving and not receiving treatment with topical NSAIDs was studied, also satisfaction of patients with treatment was taken into account.
Results and conclusion. During the retrospective snapshot analysis of clinical cards, 1224 patients with knee joints OA found that the most frequently medicine used in real practice of topical NSAIDs is a Voltaren Emulgel. Topical NSAIDs more often than oral shapes, are used by patients having comorbide pathology. By that doing, the residual intensity of pain in joints and satisfaction with the treatment of individuals using only topical NSAIDs are comparable to those when taking only oral NSAIDs or combinations of topical and oral NSAIDs.
Keywords: treatment side effects, topical NSAIDs, knee osteoarthritis, comorbidity
Read entire article

Literature


  1. Мазуров В.И., Гайдукова И.З., Беляева И.Б. Клиническая ревматология. 3-е издание, переработанное и дополненное. Руководство для врачей. М.: Е-ното. 2021; 696 с. [Mazurov V.I., Gaidukova I.Z., Belyaeva I.B. Clinical rheumatology. 3rd edition, revised and enlarged. A guide for doctors. Moscow: E-noto. 2017; 696 pp. (In Russ.)]. ISBN: 978-5-906023-26-1.

  2. Погожева Е.Ю., Амирджанова В.Н., Каратеев А.Е. Обзор обновленных клинических рекомендаций по лечению больных остеоартритом: фокус на локальные формы нестероидных противовоспалительных препаратов. Consilium Medicum. 2020; 9: 76–81. [Pogozheva E.Yu., Amirdzhanova V.N., Karateev A.E. Review of updated clinical guidelines for the treatment of patients with osteoarthritis: focus on the topical nonsteroidal anti-inflammatory drugs. Consilium Medicum. 2020; 9: 76–81 (In Russ.)]. https://dx.doi.org/10.26442/20751753.2020.9.200396.

  3. Bannuru R.R., Osani M.C., Vaysbrot E.E. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019; 27(11): 1578–89. doi: 10.1016/j.joca.2019.06.011.

  4. Zeng C., Zhang W., Doherty M. et al. Initial analgesic prescriptions for osteoarthritis in the United Kingdom, 2000-2016. Rheumatology (Oxford). 2021; 60(1): 147–59. doi: 10.1093/rheumatology/keaa244.

  5. Palazzo C., Nguyen C., Lefevre-Colau M.M. et al. Risk factors and burden of osteoarthritis. Ann Phys Rehabil Med. 2016; 59(3): 134–38. doi: 10.1016/j.rehab.2016.01.006.

  6. Courties A., Sellam J., Berenbaum F. Metabolic syndrome-associated osteoarthritis. Curr Opin Rheumatol. 2017; 29(2): 214–22. doi: 10.1097/BOR.0000000000000373.

  7. Hall A.J., Stubbs B., Mamas M.A. et al. Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. Eur J Prev Cardiol. 2016; 23(9): 938–46. doi: 10.1177/2047487315610663.

  8. Fernandes G.S., Valdes A.M. Cardiovascular disease and osteoarthritis: common pathways and patient outcomes. Eur J Clin Invest. 2015; 45(4): 405–14. doi: 10.1111/eci.12413.

  9. Bournia V.K., Kitas G., Protogerou A.D., Sfikakis P.P. Impact of non-steroidal anti-inflammatory drugs on cardiovascular risk: Is it the same in osteoarthritis and rheumatoid arthritis? Mod Rheumatol. 2017; 27(4): 559–69. doi: 10.1080/14397595.2016.1232332.

  10. Мазуров В.И., Авлохова С.Р., Лесняк О.М. Ревматология. Фармакотерапия без ошибок. Руководство для врачей. М.: Е-ното. 2017; 528 с. [Mazurov V.I., Avlokhova S.R., Lesnyak O.M. Rheumatology. Pharmacotherapy without mistakes. A guide for doctors. Moscow: E-noto. 2017; 528 pp. (In Russ.)]. ISBN: 978-5-906023-17-9.

  11. Rannou F., Pelletier J.P., Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016; 45(4 Suppl): S18–21. doi: 10.1016/j.semarthrit.2015.11.007.

  12. Whelton A., Gibofsky A. Minimizing cardiovascular complications during the treatment of osteoarthritis. Am J Ther. 2011; 18(6): 466–76. doi: 10.1097/MJT.0b013e3181e1e218.

  13. Tieppo Francio V., Davani S., Towery C., Brown T.L. Oral versus topical diclofenac sodium in the treatment of osteoarthritis. J Pain Palliat Care Pharmacother. 2017; 31(2): 113–20. doi: 10.1080/15360288.2017.1301616.

  14. Zeng C., Doherty M., Persson M.S.M. et al. Comparative efficacy and safety of acetaminophen, topical and oral non-steroidal anti-inflammatory drugs for knee osteoarthritis: evidence from a network meta-analysis of randomized controlled trials and real-world data. Osteoarthritis Cartilage. 2021; 29(9): 1242–51. doi: 10.1016/j.joca.2021.06.004.

  15. Toda K. Are topical non-steroidal anti-inflammatory drugs (NSAIDs) safer than oral NSAIDs? Or are the adverse effects of topical NSAIDs comparable to those of oral NSAIDs? Osteoarthritis Cartilage. 2021; 29(11): 1624–25. doi: 10.1016/j.joca.2021.08.010.

  16. Zeng C., Wei J., Persson M.S.M. et al. Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: A systematic review and network meta-analysis of randomised controlled trials and observational studies. Br J Sports Med. 2018; 52(10): 642–50. doi: 10.1136/bjsports-2017-098043.

  17. Persson M.S.M., Stocks J., Walsh D.A. et al. The relative efficacy of topical non-steroidal anti-inflammatory drugs and capsaicin in osteoarthritis: a network meta-analysis of randomised controlled trials. Osteoarthritis Cartilage. 2018; 26(12): 1575–82. doi: 10.1016/j.joca.2018.08.008.

  18. McMahon S.B., Dargan P., Lanas A., Wiffen P. The burden of musculoskeletal pain and the role of topical non-steroidal anti-inflammatory drugs (NSAIDs) in its treatment. Ten underpinning statements from a global pain faculty. Curr Med Res Opin. 2021; 37(2): 287–92. doi: 10.1080/03007995.2020.1847718.

  19. Maloney J., Pew S., Wie C. et al. Comprehensive review of topical analgesics for chronic pain. Curr Pain Headache Rep. 2021; 25(2): 7. doi: 10.1007/s11916-020-00923-2.

  20. Wolff D.G., Christophersen C., Brown S.M., Mulcahey M.K. Topical nonsteroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Phys Sportsmed. 2021; 49(4): 381–91. doi: 10.1080/00913847.2021.1886573.

  21. Hagen M., Baker M. Skin penetration and tissue permeation after topical administration of diclofenac. Curr Med Res Opin. 2017; 33(9): 1623–34. doi: 10.1080/03007995.2017.1352497.


About the Autors

Inna Z. Gaydukova, MD, Deputy Director of the Research Institute of Rheumatology, I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia, professor of the Department of therapy, rheumatology, expertise of temporary disability and medical care quality named after E.E. Eichwald, I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia. Address: 191015, Saint Petersburg, 41 Kirochnaya Str. E-mail: ubp1976@list.ru. ORCID: 0000-0003-3500-7256. SPIN-code: 3083-7996
Andrey R. Bashkinov, postgraduate student at the Department of therapy, rheumatology, expertise of temporary disability and medical care quality named after E.E. Eichwald, I.I. Mechnikov North-Western State Medical University of the Ministry of Healthcare of Russia, rheumatologist at Clinical Rheumatology Hospital No. 25 (Saint Petersburg). Address: 191015, Saint Petersburg, 41 Kirochnaya Str. E-mail: bashkinov-roman@mail.ru. ORCID: 0000-0001-9344-1304. SPIN-code: 5169-5066
Oksana V. Inamova, PhD, Chief physician of Clinical Rheumatology Hospital No. 25 (Saint Petersburg), Deputy Director of the Research Institute of Rheumatology of I.I. Mechnikov North-West State Medical University of the Ministry of Healthcare of Russia, assistant at the Department of therapy, rheumatology, examination of temporary disability and quality of medical care named after E.E. Eichwald, I.I. Mechnikov North-West State Medical University of the Ministry of Healthcare of Russia. Address: 191015, Saint Petersburg, 41 Kirochnaya Str. E-mail: b25@zdrav.spb.ru. ORCID: 0000-0001-9126-3639. SPIN-code: 8841-5496


Similar Articles

Back to Content

Бионика Медиа